Arrowhead (ARWR) Hits 3-Year High on Strong Earnings, FDA Approval

We recently published 10 Big Names Feasting on Gains Ahead of Thanksgiving. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the best-performing stocks on Wednesday. Arrowhead Pharmaceuticals soared to a new three-year high on Wednesday, as investors took heart from its impressive earnings performance for the full fiscal year, alongside the Food and Drug Administration’s (FDA) approval for its treatment for familial chylomicronemia syndrome (FCS). At intra-day trading, the stock soared to as high ...